Literature DB >> 29507070

Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection.

Qian Dong1, Stephanie Leroux2, Hai-Yan Shi1,3, Hai-Yan Xu4, Chen Kou5, Muhammad Wasim Khan1, Evelyne Jacqz-Aigrain6, Wei Zhao7,3.   

Abstract

Newborns with congenital cytomegalovirus (CMV) infection are at high risk for developing permanent sequelae. Intravenous ganciclovir therapy is frequently used for the treatment of congenital CMV infection. A target area under the concentration-time curve from 0 to 24 h (AUC0-24) of 40 to 50 μg · h/ml is recommended. The standard dose has resulted in a large variability in ganciclovir exposure in newborns, indicating the unmet need of dosage individualization for this vulnerable population, but the implementation of this strategy remains challenging in clinical practice. We aim to evaluate the clinical utility of model-based dosage individualization of ganciclovir in newborns using an opportunistic sampling approach. The predictive performance of a published ganciclovir population pharmacokinetic model was evaluated using an independent patient cohort. The individual dose was adjusted based on the target AUC0-24 to ensure its efficacy. A total of 26 newborns with congenital CMV infection were included in the present study. Only 11 (42.3%) patients achieved the target AUC0-24 after being given the standard dose. For all the subtherapeutic patients (achieving <80% of the target AUC) (n = 5), a model-based dosage adjustment was performed using the Bayesian estimation method combined with the opportunistic sampling strategy. The adjusted doses were increased by 28.6% to 60.0% in these five patients, and all adapted AUC0-24 values achieved the target (range, 48.6 to 66.1 μg · h/ml). The clinical utility of model-based dosing individualization of ganciclovir was demonstrated in newborns with congenital CMV infection. The population pharmacokinetic model combined with the opportunistic sampling strategy provides a clinically feasible method to adapt the ganciclovir dose in neonatal clinical practice. (This study has been registered at ClinicalTrials.gov under registration no. NCT03113344.).
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  congenital cytomegalovirus infection; ganciclovir; individualized therapy; infants; neonates; opportunistic sampling strategy; population pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 29507070      PMCID: PMC5923132          DOI: 10.1128/AAC.00075-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum.

Authors:  F Chu; C H Kiang; M L Sung; B Huang; R L Reeve; T Tarnowski
Journal:  J Pharm Biomed Anal       Date:  1999-11       Impact factor: 3.935

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.

Authors:  Chris Stockmann; Jessica K Roberts; Elizabeth D Knackstedt; Michael G Spigarelli; Catherine Mt Sherwin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-11-27       Impact factor: 4.481

3.  Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients.

Authors:  John F Spivey; Dana Singleton; Stuart Sweet; Gregory A Storch; Robert J Hayashi; Charles B Huddleston; Lara A Danziger-Isakov
Journal:  Pediatr Transplant       Date:  2007-05

Review 4.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 5.  Congenital cytomegalovirus infections.

Authors:  Gunilla Malm; Mona-Lisa Engman
Journal:  Semin Fetal Neonatal Med       Date:  2007-03-06       Impact factor: 3.926

6.  Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.

Authors:  David Villeneuve; Adam Brothers; Eric Harvey; Mariska Kemna; Yuk Law; Thomas Nemeth; Soren Gantt
Journal:  Pediatr Transplant       Date:  2012-12-13

7.  Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.

Authors:  Daolun Zhang; Anne-Laure Lapeyraque; Michel Popon; Chantal Loirat; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2003-07-23       Impact factor: 3.714

8.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

Review 9.  Treatment of congenital cytomegalovirus: where are we now?

Authors:  Marian G Michaels
Journal:  Expert Rev Anti Infect Ther       Date:  2007-06       Impact factor: 5.091

10.  New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.

Authors:  A Åsberg; A Bjerre; M Neely
Journal:  Pediatr Transplant       Date:  2013-10-23
View more
  3 in total

1.  Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group.

Authors:  Olivia Boyer; Franz Schaefer; Dieter Haffner; Detlef Bockenhauer; Tuula Hölttä; Sandra Bérody; Hazel Webb; Marie Heselden; Beata S Lipska-Ziętkiewicz; Fatih Ozaltin; Elena Levtchenko; Marina Vivarelli
Journal:  Nat Rev Nephrol       Date:  2021-01-29       Impact factor: 28.314

Review 2.  Review of Scavenged Sampling for Sustainable Therapeutic Drug Monitoring: Do More With Less.

Authors:  Stef Schouwenburg; Robin F J van der Klip; Tim J L Smeets; Nicole G M Hunfeld; Robert B Flint; Matthijs de Hoog; Henrik Endeman; Birgit C P Koch; Enno D Wildschut; Alan Abdulla
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

Review 3.  The Pharmacokinetics of Beta-Lactam Antibiotics Using Scavenged Samples in Pediatric Intensive Care Patients: The EXPAT Kids Study Protocol.

Authors:  Stef Schouwenburg; Enno D Wildschut; M de Hoog; Birgit C P Koch; Alan Abdulla
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.